MeSH term
Frequency | Condition_Probility | Adult | 116 | 0.0 |
Antihypertensive Agents/therapeutic use | 2 | 2.0 |
Blood Glucose/metabolism | 3 | 0.0 |
Humans | 735 | 0.0 |
Male | 162 | 0.0 |
Middle Aged | 110 | 0.0 |
Reference Values | 13 | 0.0 |
Risk Factors | 5 | 0.0 |
Aged | 75 | 0.0 |
Aged, 80 and over | 25 | 0.0 |
Fatal Outcome | 3 | 0.0 |
Female | 159 | 0.0 |
Animals | 301 | 0.0 |
Swine | 4 | 0.0 |
Gene Library | 5 | 0.0 |
Molecular Sequence Data | 78 | 0.0 |
Mutagenesis, Insertional | 2 | 0.0 |
Polymerase Chain Reaction | 21 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 483 | 0.0 |
Sequence Deletion | 8 | 0.0 |
Antigens, CD36/*genetics | 19 | 90.0 |
Base Sequence | 45 | 0.0 |
Exons/genetics | 3 | 0.0 |
Genotype | 11 | 0.0 |
Insulin Resistance/genetics | 4 | 10.0 |
Introns/genetics | 2 | 0.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
COS Cells | 15 | 0.0 |
Cholesterol/metabolism | 8 | 2.0 |
Chromatography, Affinity | 5 | 0.0 |
Lipids/*metabolism | 7 | 3.0 |
Lipoproteins, HDL/*metabolism | 7 | 5.0 |
Lipoproteins, LDL/metabolism | 17 | 7.0 |
*Membrane Proteins | 48 | 4.0 |
*Receptors, Immunologic | 30 | 18.0 |
*Receptors, Lipoprotein | 41 | 31.0 |
Research Support, U.S. Gov't, P.H.S. | 208 | 0.0 |
Spodoptera | 2 | 0.0 |
Transfection | 51 | 0.0 |
Antigens, CD36 | 123 | 93.0 |
Carrier Proteins/metabolism | 5 | 0.0 |
Disease Models, Animal | 10 | 0.0 |
Exercise/*physiology | 2 | 0.0 |
Fatty Acids/*metabolism | 12 | 14.0 |
Membrane Glycoproteins/metabolism | 14 | 2.0 |
*Neoplasm Proteins | 5 | 0.0 |
*Nerve Tissue Proteins | 3 | 0.0 |
Organic Anion Transporters/metabolism | 2 | 33.0 |
Rats | 39 | 0.0 |
*Tumor Suppressor Proteins | 5 | 0.0 |
Antigens, CD36/*metabolism | 46 | 90.0 |
CHO Cells | 39 | 1.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Hamsters | 44 | 1.0 |
Macrophages/*metabolism | 14 | 5.0 |
Mice | 93 | 0.0 |
Mice, Inbred C57BL | 16 | 0.0 |
Molecular Structure | 3 | 0.0 |
Oxidation-Reduction | 28 | 2.0 |
Peroxidase/metabolism | 3 | 2.0 |
Protein Binding | 27 | 0.0 |
Receptors, Immunologic/*metabolism | 8 | 4.0 |
Antigenic Variation | 3 | 10.0 |
Erythrocytes/*parasitology | 16 | 53.0 |
*Gene Expression Regulation | 8 | 0.0 |
Malaria, Falciparum/*parasitology | 11 | 78.0 |
Multigene Family | 5 | 0.0 |
Placenta/metabolism/*parasitology | 2 | 100.0 |
Plasmodium falciparum/*genetics/metabolism | 2 | 100.0 |
Pregnancy | 22 | 0.0 |
Pregnancy Complications, Parasitic/parasitology | 2 | 100.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 31 | 0.0 |
Endothelium, Vascular/*drug effects | 2 | 3.0 |
Receptors, Cytoplasmic and Nuclear/physiology | 4 | 12.0 |
*Thiazolidinediones | 10 | 10.0 |
Transcription Factors/physiology | 4 | 1.0 |
Antigens, CD36/genetics | 6 | 46.0 |
Cluster Analysis | 5 | 2.0 |
Cohort Studies | 4 | 0.0 |
Comparative Study | 61 | 0.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Antigens, CD36/*biosynthesis/genetics/physiology | 2 | 100.0 |
Antigens, CD8/*biosynthesis | 2 | 10.0 |
Cells, Cultured | 127 | 0.0 |
Dendritic Cells/*immunology/*metabolism | 3 | 17.0 |
Injections, Intravenous | 2 | 0.0 |
Mice, Knockout | 16 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
Phagocytosis/immunology | 2 | 3.0 |
Coculture Techniques | 5 | 0.0 |
Mice, Inbred BALB C | 7 | 0.0 |
Apoptosis/physiology | 2 | 0.0 |
Erythrocytes/parasitology | 14 | 40.0 |
Fatty Acids/metabolism | 4 | 3.0 |
Integrins/metabolism | 6 | 3.0 |
Receptors, Collagen | 6 | 8.0 |
Signal Transduction/physiology | 6 | 0.0 |
Arteriosclerosis/prevention & control | 3 | 12.0 |
Biological Transport | 14 | 1.0 |
Amino Acid Sequence | 50 | 0.0 |
Antigens, CD36/chemistry/*metabolism | 4 | 80.0 |
Cell Line | 77 | 0.0 |
Endocytosis | 6 | 1.0 |
Lipoproteins, LDL/*metabolism | 28 | 15.0 |
Sequence Homology, Amino Acid | 11 | 0.0 |
Cell Adhesion/drug effects | 18 | 4.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Gene Expression Regulation/drug effects | 7 | 0.0 |
Platelet Aggregation/drug effects | 5 | 2.0 |
Protein Kinase C/antagonists & inhibitors | 4 | 3.0 |
Receptors, Immunologic/metabolism | 7 | 4.0 |
Antigens, CD/analysis | 37 | 2.0 |
Chromosome Aberrations | 5 | 0.0 |
DNA, Viral/analysis | 3 | 0.0 |
Dendritic Cells/*pathology | 2 | 5.0 |
Gene Rearrangement | 2 | 0.0 |
HLA-DR Antigens/analysis | 8 | 1.0 |
Immunophenotyping | 41 | 1.0 |
Karyotyping | 11 | 0.0 |
Skin Neoplasms/*pathology | 2 | 2.0 |
Adolescent | 42 | 0.0 |
Angiopoietin-2 | 2 | 3.0 |
Antigens, CD36/analysis | 13 | 86.0 |
Immunohistochemistry | 46 | 0.0 |
Vascular Endothelial Growth Factor A | 5 | 0.0 |
Vascular Endothelial Growth Factors | 4 | 0.0 |
Antigens, CD36/drug effects | 2 | 100.0 |
Child | 46 | 0.0 |
Phagocytosis/drug effects | 3 | 3.0 |
Tumor Necrosis Factor-alpha/secretion | 3 | 2.0 |
Up-Regulation/drug effects | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 27 | 0.0 |
Tretinoin/*pharmacology | 3 | 0.0 |
Acute Disease | 8 | 0.0 |
Antigens, CD/metabolism | 19 | 2.0 |
Bone Marrow/pathology | 4 | 1.0 |
Cell Cycle | 2 | 0.0 |
Flow Cytometry | 86 | 1.0 |
Hematopoietic Stem Cells | 2 | 3.0 |
Phenotype | 40 | 0.0 |
Dose-Response Relationship, Drug | 16 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 7 | 0.0 |
Immunosuppressive Agents/*pharmacology | 2 | 0.0 |
Lymphocyte Culture Test, Mixed | 3 | 0.0 |
Tumor Necrosis Factor-alpha/analysis | 2 | 0.0 |
Up-Regulation | 17 | 0.0 |
Blotting, Western | 25 | 0.0 |
Cell Extracts/chemistry | 2 | 8.0 |
Fluorescent Antibody Technique | 21 | 0.0 |
Precipitin Tests | 8 | 0.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
*Sialoglycoproteins | 4 | 30.0 |
Antigens, CD36/biosynthesis/*genetics | 3 | 75.0 |
B-Lymphocytes/*metabolism | 3 | 1.0 |
Cloning, Molecular | 13 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Genes, Reporter | 5 | 0.0 |
RNA, Messenger/biosynthesis | 11 | 0.0 |
Sequence Alignment | 6 | 0.0 |
Transcription Factors/*metabolism | 5 | 0.0 |
Time Factors | 23 | 0.0 |
*Ultraviolet Rays | 2 | 0.0 |
Antigens, CD/*analysis/immunology | 3 | 10.0 |
Blood Platelets/*immunology | 8 | 10.0 |
Hemostasis | 2 | 1.0 |
Antigens, CD31/metabolism | 2 | 2.0 |
Antigens, CD36/metabolism | 38 | 77.0 |
Apoptosis/drug effects | 2 | 0.0 |
Cell Division/drug effects/physiology | 2 | 0.0 |
Mice, Nude | 4 | 0.0 |
Proliferating Cell Nuclear Antigen/metabolism | 2 | 0.0 |
Antibodies/pharmacology | 6 | 1.0 |
Cholesterol/*metabolism | 6 | 2.0 |
Kinetics | 22 | 0.0 |
Rats, Wistar | 6 | 0.0 |
Chromosome Mapping | 10 | 0.0 |
Linkage (Genetics) | 4 | 0.0 |
Membrane Glycoproteins/*genetics | 2 | 0.0 |
Organic Anion Transporters/*genetics | 2 | 33.0 |
Quantitative Trait, Heritable | 4 | 7.0 |
Fatty Acids/genetics/*metabolism | 2 | 66.0 |
*Gene Deletion | 2 | 0.0 |
Biological Markers | 8 | 0.0 |
Follow-Up Studies | 4 | 0.0 |
Leukocytes/immunology | 2 | 1.0 |
Prognosis | 10 | 0.0 |
Cell Line, Transformed | 6 | 0.0 |
*Exons | 2 | 0.0 |
Muscle, Smooth, Vascular/*metabolism | 2 | 4.0 |
Oligonucleotides, Antisense/pharmacology | 2 | 0.0 |
Transcription, Genetic | 15 | 0.0 |
Tumor Cells, Cultured | 54 | 0.0 |
Apoptosis/*physiology | 5 | 0.0 |
In Vitro | 33 | 0.0 |
Jurkat Cells | 3 | 0.0 |
Phagocytosis | 14 | 3.0 |
Receptors, Cell Surface/*physiology | 6 | 2.0 |
Receptors, IgG/metabolism | 2 | 2.0 |
Antigens, CD36/*physiology | 14 | 87.0 |
Glycosylation End Products, Advanced/*metabolism | 4 | 9.0 |
Receptors, Immunologic/*physiology | 7 | 4.0 |
Recombinant Proteins/metabolism | 8 | 0.0 |
Biological Markers/blood | 6 | 0.0 |
Case-Control Studies | 12 | 0.0 |
Cell Adhesion | 71 | 5.0 |
Cell Communication | 6 | 2.0 |
Child, Preschool | 31 | 0.0 |
Endothelium, Vascular/*cytology | 3 | 1.0 |
Infant | 19 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Dendritic Cells/immunology/pathology | 2 | 10.0 |
Treatment Outcome | 3 | 0.0 |
3T3 Cells | 5 | 0.0 |
Adipocytes/metabolism | 3 | 7.0 |
Endothelium/cytology/metabolism | 2 | 11.0 |
Hepatocytes/metabolism | 2 | 2.0 |
Lipase/metabolism | 2 | 3.0 |
Macrophages, Peritoneal/metabolism | 3 | 13.0 |
Mice, Inbred Strains | 2 | 0.0 |
Tissue Distribution | 5 | 0.0 |
Antigens, CD36/genetics/*physiology | 10 | 100.0 |
Myocardium/metabolism | 3 | 1.0 |
Insulin Resistance | 2 | 1.0 |
Monocytes/drug effects/immunology | 2 | 5.0 |
Prospective Studies | 5 | 0.0 |
Lipopolysaccharides/pharmacology | 3 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 13 | 0.0 |
Thrombospondin 1/metabolism/*physiology | 2 | 40.0 |
Transforming Growth Factor beta/metabolism | 2 | 1.0 |
Biological Markers/analysis | 6 | 0.0 |
Antigens, CD/*immunology | 8 | 1.0 |
Antigens, CD14/immunology | 2 | 3.0 |
Receptors, Cell Surface/*immunology | 2 | 2.0 |
Receptors, Immunologic/immunology | 2 | 1.0 |
Disease Progression | 5 | 0.0 |
Gene Expression Regulation | 15 | 0.0 |
Arteriosclerosis/*physiopathology | 3 | 17.0 |
Foam Cells/physiology | 2 | 50.0 |
Macrophages/*physiology | 3 | 3.0 |
Apoptosis | 7 | 0.0 |
Antigens, CD36/*biosynthesis | 3 | 100.0 |
*Apoptosis | 9 | 0.0 |
Arachidonate 15-Lipoxygenase/metabolism | 2 | 50.0 |
Phospholipases A/metabolism | 2 | 3.0 |
Trans-Activation (Genetics) | 4 | 0.0 |
*Up-Regulation | 3 | 1.0 |
Hydroxycholesterols/pharmacology | 2 | 7.0 |
Models, Biological | 16 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
Macrophages/physiology | 5 | 6.0 |
Peptide Fragments/metabolism/pharmacology | 2 | 6.0 |
Reactive Oxygen Species/*metabolism | 2 | 1.0 |
Retinoid X Receptors | 5 | 1.0 |
Scattering, Radiation | 2 | 1.0 |
Thiazoles/pharmacology | 6 | 5.0 |
Antigens, CD/*metabolism | 13 | 2.0 |
Langerhans Cells/*metabolism | 2 | 10.0 |
Membrane Glycoproteins/*metabolism | 8 | 1.0 |
Antigens, CD14/*metabolism | 2 | 2.0 |
Ligands | 23 | 0.0 |
Lipopolysaccharides/*pharmacology | 2 | 0.0 |
Monocytes/*metabolism | 8 | 2.0 |
Receptors, Cell Surface/metabolism | 6 | 1.0 |
ATP-Binding Cassette Transporters/metabolism | 2 | 4.0 |
Cholesterol Esters/*metabolism | 4 | 4.0 |
Down-Regulation | 9 | 0.0 |
Lipids/metabolism | 6 | 1.0 |
Lipoproteins, VLDL/*metabolism | 2 | 2.0 |
RNA, Messenger/analysis | 16 | 0.0 |
Receptors, Lipoprotein/genetics/metabolism | 2 | 50.0 |
Antigens, CD36/physiology | 12 | 66.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Eosinophils/*physiology | 2 | 4.0 |
Integrins/*physiology | 4 | 4.0 |
Antigens, CD36/genetics/*metabolism | 12 | 80.0 |
Receptors, Lipoprotein/metabolism | 4 | 40.0 |
Binding Sites | 23 | 0.0 |
Cell Membrane/metabolism | 16 | 1.0 |
Dextrans/pharmacology | 2 | 13.0 |
Dimerization | 3 | 0.0 |
Endothelium, Vascular/*metabolism | 4 | 1.0 |
Amino Acid Substitution | 2 | 0.0 |
Blood Pressure/physiology | 2 | 1.0 |
Insulin Resistance/*genetics | 6 | 7.0 |
Japan | 4 | 0.0 |
Lipids/blood | 3 | 0.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Antigen-Antibody Reactions | 4 | 1.0 |
Cell Adhesion/drug effects/immunology | 2 | 10.0 |
Oxidation-Reduction/drug effects | 2 | 2.0 |
U937 Cells | 4 | 0.0 |
Blotting, Northern | 10 | 0.0 |
Mutation | 14 | 0.0 |
Glycosylation | 6 | 0.0 |
Microspheres | 5 | 2.0 |
P-Selectin/*metabolism | 2 | 9.0 |
Plasmodium falciparum/*metabolism | 6 | 75.0 |
Polysaccharides/pharmacology | 3 | 20.0 |
Recombinant Fusion Proteins/metabolism | 7 | 0.0 |
Antibodies, Monoclonal/immunology | 17 | 1.0 |
Integrins/*immunology | 2 | 12.0 |
Phagocytosis/*immunology | 4 | 7.0 |
Pigment Epithelium of Eye/cytology/*immunology | 2 | 50.0 |
*Receptors, Vitronectin | 2 | 14.0 |
Rod Outer Segments/*immunology | 2 | 100.0 |
Muscle, Skeletal/metabolism | 2 | 1.0 |
Triglycerides/blood | 2 | 0.0 |
Antigens, CD36/immunology/*metabolism | 4 | 66.0 |
Cell Differentiation/drug effects | 14 | 1.0 |
DNA Mutational Analysis | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Response Elements/genetics | 3 | 1.0 |
Cell Line, Tumor | 7 | 0.0 |
Gene Expression/drug effects | 8 | 1.0 |
Lipoproteins/metabolism | 2 | 1.0 |
Phosphorylation | 10 | 0.0 |
Promoter Regions (Genetics)/physiology | 2 | 1.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Antigens, CD/genetics | 5 | 3.0 |
Chromosomes, Human, Pair 7 | 2 | 1.0 |
Colony-Forming Units Assay | 5 | 0.0 |
Exons | 4 | 0.0 |
Immunoglobulin G/blood | 3 | 1.0 |
Monocytes/*physiology | 5 | 3.0 |
Dendritic Cells/*physiology | 2 | 2.0 |
Interleukin-12/biosynthesis | 2 | 2.0 |
Liver/cytology/*metabolism | 2 | 2.0 |
Cholesterol Esters/metabolism | 11 | 10.0 |
Lipoproteins, LDL/*metabolism/pharmacology | 2 | 28.0 |
Antigens, Surface/metabolism | 2 | 1.0 |
Blood Platelets/*metabolism | 14 | 5.0 |
Cell Adhesion Molecules/*metabolism | 11 | 4.0 |
Microscopy, Confocal | 10 | 1.0 |
P-Selectin/pharmacology | 2 | 100.0 |
Platelet Activation/*physiology | 6 | 10.0 |
Stress, Mechanical | 5 | 1.0 |
Membrane Glycoproteins/genetics/*metabolism | 2 | 1.0 |
Organ Specificity | 6 | 0.0 |
RNA, Messenger/metabolism | 17 | 0.0 |
Antigens, CD36/chemistry/*physiology | 2 | 100.0 |
Inflammation/etiology | 3 | 8.0 |
Malaria, Falciparum/etiology | 2 | 100.0 |
Neovascularization, Physiologic | 2 | 1.0 |
Immunoglobulin M/pharmacology | 2 | 20.0 |
Microscopy, Immunoelectron | 5 | 0.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*physiology | 4 | 7.0 |
Transcription Factors/*physiology | 4 | 0.0 |
Prevalence | 2 | 0.0 |
Cell Division/drug effects | 11 | 0.0 |
Liver/*metabolism | 2 | 0.0 |
Pyrimidines/pharmacology | 2 | 1.0 |
Heart/*radionuclide imaging | 6 | 27.0 |
Tomography, Emission-Computed, Single-Photon | 4 | 7.0 |
Cell Cycle/drug effects | 2 | 0.0 |
Thiazoles/*pharmacology | 2 | 3.0 |
Trans-Activation (Genetics)/drug effects | 2 | 0.0 |
Antigens, CD36/immunology | 3 | 42.0 |
Antigens, Human Platelet/*immunology | 4 | 36.0 |
Blood Platelets/immunology | 10 | 14.0 |
Platelet Count | 7 | 1.0 |
Heparin/metabolism | 2 | 1.0 |
Intercellular Adhesion Molecule-1/metabolism | 12 | 6.0 |
Receptors, Cell Surface/*metabolism | 5 | 0.0 |
*Rosette Formation | 10 | 23.0 |
Severity of Illness Index | 6 | 0.0 |
Interleukin-6/metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 8 | 1.0 |
Alleles | 3 | 0.0 |
Antigens, CD36/*genetics/metabolism | 7 | 77.0 |
Gene Frequency | 6 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Microscopy, Fluorescence | 10 | 0.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Extracellular Matrix Proteins/metabolism | 2 | 2.0 |
Signal Transduction | 15 | 0.0 |
Matched-Pair Analysis | 2 | 2.0 |
Reticulocytes/*metabolism | 2 | 22.0 |
Statistics, Nonparametric | 2 | 0.0 |
Calcium/*metabolism | 3 | 0.0 |
P-Selectin/metabolism | 2 | 4.0 |
Platelet Activation/drug effects | 2 | 3.0 |
Flow Cytometry/*methods | 2 | 0.0 |
*Platelet Activation | 5 | 3.0 |
Platelet Membrane Glycoproteins/analysis | 6 | 8.0 |
Adenoviridae/genetics | 2 | 0.0 |
Gene Expression | 10 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Rats, Inbred SHR | 7 | 8.0 |
*Antigens, CD36 | 8 | 100.0 |
Animals, Congenic | 2 | 11.0 |
Blood Platelets/metabolism | 7 | 3.0 |
Membrane Glycoproteins/deficiency/genetics/*physiology | 2 | 13.0 |
Triglycerides/metabolism | 2 | 1.0 |
Antigens, CD36/*immunology | 11 | 100.0 |
Apoptosis/*immunology | 3 | 1.0 |
Cell Differentiation | 23 | 0.0 |
Integrin alphaV | 3 | 11.0 |
Plasmodium falciparum/immunology | 3 | 14.0 |
T-Lymphocytes/immunology | 4 | 0.0 |
DNA Primers | 7 | 0.0 |
Gene Expression Regulation/*drug effects | 8 | 1.0 |
Nucleic Acid Conformation | 2 | 0.0 |
Monocytes/immunology | 8 | 2.0 |
*Phytotherapy | 4 | 4.0 |
Binding, Competitive | 14 | 0.0 |
Foam Cells/*metabolism | 2 | 14.0 |
Lipids/analysis | 3 | 6.0 |
Receptors, IgG/*analysis | 2 | 6.0 |
Age Factors | 2 | 0.0 |
Antigens, CD36/*analysis | 7 | 87.0 |
Sensitivity and Specificity | 7 | 0.0 |
Kenya | 3 | 6.0 |
Cell Movement | 5 | 0.0 |
Endothelium, Vascular/cytology/*metabolism | 2 | 1.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Intercellular Adhesion Molecule-1/genetics/metabolism | 2 | 11.0 |
Vascular Cell Adhesion Molecule-1/genetics/metabolism | 2 | 28.0 |
Plasmodium falciparum/*immunology | 4 | 9.0 |
Prostaglandin D2/analogs & derivatives/pharmacology | 2 | 40.0 |
Protozoan Proteins/metabolism | 3 | 37.0 |
Tretinoin/pharmacology | 2 | 0.0 |
Antigens, CD36/*biosynthesis/genetics | 4 | 80.0 |
Arteriosclerosis/*metabolism/pathology | 2 | 5.0 |
Monocytes/drug effects/*metabolism | 5 | 4.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 6 | 4.0 |
Transcription Factors/metabolism | 8 | 0.0 |
Antibodies, Monoclonal/pharmacology | 12 | 1.0 |
Antibody Specificity | 6 | 0.0 |
Collagen/*metabolism | 4 | 2.0 |
Lipoproteins, LDL/metabolism/pharmacology | 2 | 33.0 |
Macrophages/cytology/drug effects/*metabolism | 2 | 18.0 |
Monocytes/cytology/*metabolism | 2 | 7.0 |
Cell Separation | 13 | 1.0 |
Platelet Activation | 8 | 5.0 |
Platelet Adhesiveness/drug effects | 4 | 9.0 |
Rheology | 4 | 5.0 |
Lipoproteins, HDL/metabolism | 6 | 5.0 |
Anemia, Sickle Cell/*blood/pathology | 2 | 50.0 |
Antigens, CD/blood | 7 | 2.0 |
Antigens, CD36/blood | 4 | 80.0 |
Erythrocyte Aggregation | 2 | 15.0 |
Erythrocytes/*metabolism/pathology | 2 | 28.0 |
Lipoproteins, LDL/chemistry/*metabolism | 3 | 23.0 |
Monocytes/physiology | 2 | 1.0 |
Vitamin E/*pharmacology | 2 | 9.0 |
DNA-Binding Proteins/metabolism | 4 | 0.0 |
Receptors, Cytoplasmic and Nuclear/agonists/genetics/*metabolism | 2 | 40.0 |
Transcription Factors/agonists/genetics/*metabolism | 2 | 50.0 |
Endocytosis/drug effects/*physiology | 2 | 9.0 |
Glycosylation End Products, Advanced/*pharmacokinetics | 2 | 100.0 |
Iodine Radioisotopes/pharmacokinetics | 2 | 28.0 |
Lipoproteins, LDL/pharmacology | 2 | 4.0 |
Biological Transport/drug effects | 2 | 0.0 |
Lipoproteins, LDL/*pharmacology | 8 | 13.0 |
Macrophages/drug effects/*physiology | 4 | 25.0 |
RNA, Messenger/genetics | 12 | 0.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
Insulin Resistance/*physiology | 2 | 2.0 |
*Organic Anion Transporters | 6 | 31.0 |
Administration, Topical | 2 | 1.0 |
Antibodies, Monoclonal | 39 | 1.0 |
Detergents/pharmacology | 2 | 1.0 |
Integrin alpha6beta1 | 2 | 10.0 |
*Membrane Glycoproteins | 8 | 0.0 |
Antigens, CD/*analysis | 32 | 4.0 |
Antigens, CD14/analysis | 3 | 2.0 |
Leukocytes, Mononuclear/*immunology | 2 | 1.0 |
Lipoproteins, HDL Cholesterol/blood | 2 | 0.0 |
Arteriosclerosis/metabolism | 2 | 3.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 13 | 0.0 |
Plasmodium falciparum | 13 | 38.0 |
*Intercellular Signaling Peptides and Proteins | 3 | 0.0 |
Macrophages/*drug effects/metabolism | 5 | 14.0 |
Monocytes/cytology | 4 | 3.0 |
Peptide Fragments/genetics/metabolism | 2 | 1.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
DNA Primers/genetics | 2 | 0.0 |
Malaria, Falciparum/immunology | 2 | 28.0 |
Point Mutation | 4 | 0.0 |
Protein Structure, Tertiary | 5 | 0.0 |
Dendritic Cells/*immunology/metabolism | 3 | 6.0 |
Animals, Genetically Modified | 2 | 0.0 |
Glucose Tolerance Test | 2 | 0.0 |
Endothelium, Vascular/cytology | 7 | 2.0 |
Substrate Specificity | 2 | 0.0 |
Cell Adhesion Molecules/metabolism | 16 | 6.0 |
Endothelium, Vascular/*cytology/drug effects/metabolism | 2 | 10.0 |
Organ Culture Techniques | 3 | 0.0 |
Placenta/*blood supply | 2 | 12.0 |
Tumor Necrosis Factor-alpha/pharmacology | 10 | 0.0 |
Protein Processing, Post-Translational | 4 | 0.0 |
Transcription, Genetic/drug effects | 4 | 0.0 |
DNA, Complementary/genetics | 9 | 0.0 |
Gene Deletion | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
*Insulin Resistance | 3 | 1.0 |
Syndrome | 2 | 0.0 |
Fatty Acids, Nonesterified/*metabolism | 4 | 15.0 |
Linkage Disequilibrium | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
*Immunotherapy | 2 | 1.0 |
Cattle | 15 | 0.0 |
Signal Transduction/*physiology | 3 | 0.0 |
Antigens, CD36/genetics/metabolism | 7 | 63.0 |
Fluorescent Dyes | 4 | 1.0 |
Rats, Sprague-Dawley | 6 | 0.0 |
Receptors, LDL/genetics/metabolism | 3 | 14.0 |
Macrophage-1 Antigen/analysis | 2 | 4.0 |
Malaria, Falciparum/blood | 2 | 40.0 |
*Phagocytosis | 7 | 5.0 |
Plasmodium falciparum/*pathogenicity | 3 | 37.0 |
p38 Mitogen-Activated Protein Kinases | 5 | 0.0 |
Antigens, CD36/chemistry/genetics/*metabolism | 3 | 100.0 |
Neovascularization, Pathologic | 3 | 0.0 |
Endothelium, Vascular/*parasitology | 4 | 100.0 |
Host-Parasite Relations/*physiology | 2 | 100.0 |
Mice, SCID | 4 | 0.0 |
Microcirculation | 12 | 4.0 |
Plasmodium falciparum/*physiology | 21 | 72.0 |
Skin/blood supply | 4 | 6.0 |
Chromans/pharmacology | 3 | 13.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
Receptors, LDL/biosynthesis/genetics | 2 | 66.0 |
Iodine Radioisotopes | 6 | 1.0 |
Analysis of Variance | 2 | 0.0 |
Blood Platelets/drug effects/metabolism | 2 | 4.0 |
Hemodynamic Processes | 3 | 1.0 |
Platelet Aggregation Inhibitors/*therapeutic use | 2 | 8.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/analysis | 3 | 12.0 |
Blotting, Southern | 2 | 0.0 |
*Cell Adhesion Molecules | 4 | 1.0 |
Melanoma | 7 | 7.0 |
Microscopy, Electron | 14 | 0.0 |
Cell Adhesion Molecules/*physiology | 3 | 2.0 |
*Plasmodium falciparum | 7 | 50.0 |
Immunoblotting | 10 | 0.0 |
Integrin alpha3beta1 | 2 | 6.0 |
Integrins/*metabolism | 3 | 2.0 |
Mutagenesis | 2 | 0.0 |
Polyethylene Glycols/pharmacology | 2 | 4.0 |
Blood-Brain Barrier/*physiology | 2 | 5.0 |
Up-Regulation/genetics | 3 | 3.0 |
Homozygote | 3 | 0.0 |
Predictive Value of Tests | 3 | 0.0 |
Pregnancy/*blood | 3 | 1.0 |
Rh-Hr Blood-Group System/*genetics | 2 | 2.0 |
Culture Media, Conditioned | 3 | 0.0 |
*Gene Expression | 4 | 0.0 |
Monocytes/metabolism | 8 | 2.0 |
NF-kappa B/*metabolism | 2 | 0.0 |
Thrombospondin 1/pharmacology | 2 | 66.0 |
Antigens, Differentiation/metabolism | 3 | 2.0 |
DNA Primers/chemistry | 2 | 0.0 |
Endothelial Growth Factors/pharmacology | 3 | 2.0 |
Lymphokines/pharmacology | 2 | 1.0 |
Monocytes/*cytology/drug effects/metabolism | 2 | 33.0 |
Antigens, CD36/*blood | 8 | 100.0 |
Iodine Radioisotopes/*diagnostic use/pharmacokinetics | 3 | 37.0 |
Iodobenzenes/*diagnostic use/pharmacokinetics | 4 | 80.0 |
Myocardium/*metabolism | 10 | 4.0 |
Adipose Tissue/*metabolism | 4 | 3.0 |
Antigens, CD36/*genetics/*physiology | 2 | 100.0 |
Crosses, Genetic | 2 | 0.0 |
Fatty Acids/*pharmacokinetics | 2 | 100.0 |
Antigens, CD/physiology | 5 | 2.0 |
Cell Adhesion/drug effects/*physiology | 2 | 6.0 |
Endothelium, Vascular/*physiology | 5 | 3.0 |
Erythrocytes/*parasitology/*physiology | 8 | 88.0 |
Umbilical Veins | 9 | 2.0 |
Erythrocytes/*immunology | 2 | 1.0 |
Protein Conformation | 6 | 0.0 |
Structure-Activity Relationship | 5 | 0.0 |
Antigens, CD31/physiology | 2 | 40.0 |
Erythrocyte Membrane/*parasitology | 4 | 100.0 |
Intercellular Adhesion Molecule-1/physiology | 3 | 12.0 |
L Cells (Cell Line) | 3 | 1.0 |
Aorta/cytology | 2 | 2.0 |
HL-60 Cells | 4 | 0.0 |
Lipoproteins, LDL/*pharmacokinetics | 2 | 22.0 |
Macrophages/*drug effects/*metabolism | 2 | 33.0 |
Monocytes/*drug effects/*metabolism | 2 | 14.0 |
Antigens, CD36/biosynthesis/physiology | 2 | 100.0 |
Cell Count | 6 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Immunity, Cellular | 3 | 0.0 |
Macrophages/immunology | 4 | 1.0 |
Immunohistochemistry/methods | 3 | 0.0 |
*Carrier Proteins | 3 | 0.0 |
*RNA-Binding Proteins | 2 | 0.0 |
Receptors, LDL/*genetics | 2 | 1.0 |
Antioxidants | 2 | 6.0 |
*Immunophenotyping | 5 | 2.0 |
Infant, Newborn | 10 | 0.0 |
Leukocyte Count | 3 | 0.0 |
Receptors, Cell Surface/physiology | 3 | 2.0 |
Enzyme Activation | 6 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 4 | 0.0 |
Blood Platelets/*physiology | 14 | 8.0 |
Bone Neoplasms | 2 | 9.0 |
Osteosarcoma | 2 | 2.0 |
Receptors, LDL/*metabolism | 4 | 4.0 |
Cell Adhesion/physiology | 10 | 3.0 |
Lung/*pathology | 2 | 6.0 |
Rosette Formation | 8 | 2.0 |
Thailand | 5 | 3.0 |
Cell Adhesion/immunology | 3 | 1.0 |
Chondroitin Sulfates/immunology | 2 | 100.0 |
E-Selectin/metabolism | 2 | 4.0 |
Intercellular Adhesion Molecule-1/immunology | 2 | 4.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 3 | 3.0 |
Receptors, Immunologic/*genetics | 3 | 2.0 |
Transforming Growth Factor beta/*pharmacology | 2 | 0.0 |
Receptors, Vitronectin/*metabolism | 2 | 10.0 |
Thrombospondin 1/*metabolism | 5 | 38.0 |
Macrophages/immunology/metabolism | 2 | 4.0 |
Phosphatidylserines/metabolism | 2 | 3.0 |
Apoptosis/*drug effects | 4 | 0.0 |
Calcium/metabolism | 3 | 0.0 |
Cell Differentiation/physiology | 4 | 0.0 |
Cell Division | 10 | 0.0 |
Lipids/blood/*metabolism | 2 | 11.0 |
Macrophages/*cytology | 2 | 6.0 |
Heterozygote | 4 | 0.0 |
Immunoenzyme Techniques | 12 | 0.0 |
Intercellular Adhesion Molecule-1/*metabolism | 3 | 5.0 |
Mitogen-Activated Protein Kinase 3 | 2 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 2 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*metabolism | 3 | 2.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Apoptosis/drug effects/*physiology | 2 | 0.0 |
Endothelium, Vascular/drug effects/*physiology | 3 | 5.0 |
Fibroblast Growth Factor 2/pharmacology | 4 | 1.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Peptide Fragments/pharmacology | 7 | 3.0 |
Protein-Tyrosine Kinase/metabolism | 3 | 0.0 |
Thrombospondin 1/*pharmacology | 3 | 75.0 |
Platelet Activation/*drug effects | 3 | 4.0 |
Signal Transduction/*drug effects | 2 | 0.0 |
Bronchoalveolar Lavage Fluid/cytology | 3 | 2.0 |
Eosinophils/cytology | 2 | 14.0 |
Leukocytes, Mononuclear/metabolism | 2 | 0.0 |
Antigens, CD34/*blood/immunology | 2 | 66.0 |
Fetal Blood/*cytology/immunology | 2 | 8.0 |
Immunomagnetic Separation/methods | 2 | 18.0 |
Leukapheresis | 2 | 1.0 |
Leukocytes, Mononuclear/immunology | 3 | 1.0 |
Stem Cells/cytology/immunology | 2 | 11.0 |
Lipolysis | 2 | 2.0 |
Thrombocytopenia/immunology | 2 | 22.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
*Membrane Transport Proteins | 3 | 0.0 |
Interleukin-1/*pharmacology | 2 | 0.0 |
Oligopeptides/pharmacology | 7 | 3.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 3 | 0.0 |
Collagen/metabolism | 6 | 2.0 |
Fibronectins/metabolism | 4 | 2.0 |
Phagocytosis/*physiology | 3 | 6.0 |
Thrombospondins/metabolism | 4 | 26.0 |
Blood Donors | 2 | 0.0 |
Cell Lineage | 3 | 0.0 |
Chondroitin Sulfates/metabolism | 3 | 10.0 |
Plasmodium falciparum/isolation & purification/*physiology | 2 | 100.0 |
Thrombomodulin/metabolism | 2 | 6.0 |
Cell Adhesion/genetics | 2 | 3.0 |
Erythrocytes/*metabolism/*parasitology | 3 | 50.0 |
Protozoan Proteins/genetics/metabolism | 2 | 22.0 |
Cell Adhesion/drug effects/physiology | 6 | 10.0 |
Epitopes/analysis | 3 | 1.0 |
Virulence | 5 | 2.0 |
Endothelium, Vascular/pathology | 5 | 4.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Fatty Acids/*diagnostic use | 3 | 100.0 |
Iodine Radioisotopes/*diagnostic use | 4 | 6.0 |
Iodobenzenes/*diagnostic use | 3 | 60.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
Protein Transport | 2 | 0.0 |
Reactive Oxygen Species/metabolism | 6 | 1.0 |
Thrombin/metabolism | 2 | 1.0 |
Antigens, Surface/analysis | 9 | 2.0 |
Bone Marrow Cells/cytology | 2 | 2.0 |
*Cell Differentiation | 2 | 0.0 |
Platelet Glycoprotein GPIb-IX Complex/analysis | 2 | 11.0 |
*Ploidies | 2 | 2.0 |
von Willebrand Factor/*analysis | 2 | 1.0 |
Adenosine Diphosphate/pharmacology | 4 | 3.0 |
Thrombin/pharmacology | 6 | 2.0 |
Immunologic Techniques | 3 | 0.0 |
Macrophages/drug effects/*metabolism | 4 | 6.0 |
Monocytes/*cytology | 3 | 3.0 |
Receptors, Immunologic/genetics/*metabolism | 2 | 5.0 |
Hydrogen-Ion Concentration | 8 | 0.0 |
Peptides/pharmacology | 3 | 1.0 |
Plasmodium falciparum/*growth & development | 3 | 60.0 |
Polymorphism, Genetic | 5 | 0.0 |
Thrombospondins/*pharmacology | 2 | 100.0 |
Echocardiography | 2 | 0.0 |
Cell Adhesion Molecules/physiology | 5 | 5.0 |
Plasmodium falciparum/physiology | 2 | 50.0 |
Receptors, Lipoprotein/*metabolism | 4 | 25.0 |
Heart/radionuclide imaging | 3 | 30.0 |
Tumor Stem Cell Assay | 2 | 1.0 |
Integrins/physiology | 5 | 7.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology | 3 | 4.0 |
Lovastatin/*pharmacology | 4 | 18.0 |
Cell Culture Techniques/methods | 2 | 0.0 |
Fetal Blood/cytology | 5 | 2.0 |
Transcription Factors/genetics | 3 | 0.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/*metabolism | 2 | 6.0 |
Hypoglycemic Agents/pharmacology | 2 | 6.0 |
Extracellular Matrix/physiology | 2 | 2.0 |
Receptors, Vitronectin/physiology | 2 | 25.0 |
Erythrocytes/*physiology | 2 | 4.0 |
Fluorescent Antibody Technique, Indirect | 7 | 0.0 |
*Platelet Adhesiveness | 8 | 17.0 |
Platelet Aggregation/physiology | 3 | 7.0 |
Antigens, CD36/biosynthesis | 8 | 72.0 |
Fatty Acids, Nonesterified/metabolism | 3 | 9.0 |
Rabbits | 6 | 0.0 |
Bleeding Time | 2 | 1.0 |
Platelet Aggregation | 6 | 3.0 |
Antineoplastic Agents/*therapeutic use | 2 | 0.0 |
Antigens, CD/biosynthesis | 2 | 0.0 |
Antigens, Surface/biosynthesis | 2 | 3.0 |
Leukocyte L1 Antigen Complex | 3 | 4.0 |
Tritium | 3 | 1.0 |
Peptide Library | 2 | 1.0 |
Hydrolysis | 2 | 0.0 |
Iodine Radioisotopes/metabolism | 2 | 5.0 |
Models, Structural | 2 | 1.0 |
Receptors, Immunologic/genetics/metabolism | 2 | 10.0 |
Antigens, CD36/metabolism/*physiology | 2 | 100.0 |
Glucose/*metabolism | 2 | 1.0 |
Thrombospondin 1/*physiology | 2 | 40.0 |
DNA, Complementary | 5 | 0.0 |
Gene Duplication | 2 | 1.0 |
Variation (Genetics) | 2 | 0.0 |
Annexin A5/metabolism | 2 | 2.0 |
Erythrocytes/metabolism | 3 | 1.0 |
Phosphatidylserines/*metabolism | 3 | 16.0 |
Phospholipids/*metabolism | 2 | 1.0 |
DNA Fingerprinting | 2 | 1.0 |
Antigens, Neoplasm/analysis | 4 | 1.0 |
Japan/epidemiology | 2 | 0.0 |
Chronic Disease | 2 | 0.0 |
Acetylation | 3 | 0.0 |
Antigens, CD36/immunology/*physiology | 5 | 100.0 |
Chemotaxis/drug effects | 3 | 3.0 |
Macrophages/*cytology/metabolism | 2 | 14.0 |
Monocytes | 2 | 2.0 |
Solubility | 3 | 0.0 |
Autoantibodies/*immunology | 2 | 0.0 |
Purpura, Thrombotic Thrombocytopenic/*immunology | 3 | 100.0 |
Macrophages/metabolism | 9 | 2.0 |
Thrombospondin 1/metabolism | 5 | 45.0 |
Fatty Acids/*diagnostic use/pharmacokinetics | 2 | 100.0 |
Bacterial Proteins/metabolism | 2 | 3.0 |
Molecular Weight | 13 | 0.0 |
Peptide Fragments/chemistry | 2 | 1.0 |
Peptide Mapping | 3 | 0.0 |
Carbohydrates/metabolism | 2 | 3.0 |
Endothelium, Vascular/metabolism | 4 | 1.0 |
Hemorheology | 2 | 6.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Protozoan Proteins/*metabolism | 3 | 23.0 |
Species Specificity | 6 | 0.0 |
Platelet Membrane Glycoproteins/*deficiency | 3 | 60.0 |
*Tomography, Emission-Computed, Single-Photon | 2 | 6.0 |
ADP-ribosyl Cyclase | 4 | 0.0 |
Antigens, CD/*analysis/*biosynthesis | 2 | 40.0 |
HLA-DR Antigens/analysis/biosynthesis | 2 | 40.0 |
Histocompatibility Antigens Class I/immunology | 2 | 1.0 |
Antigens, Differentiation, Myelomonocytic/metabolism | 2 | 1.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Receptors, LDL/metabolism | 2 | 2.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Cell Adhesion Molecules | 5 | 9.0 |
Erythrocytes/immunology/*parasitology | 5 | 55.0 |
*Antigens, CD | 2 | 0.0 |
Genes, Protozoan | 3 | 10.0 |
Saimiri | 5 | 15.0 |
Bone Marrow Transplantation/*immunology | 2 | 1.0 |
Histocompatibility Testing | 2 | 0.0 |
Integrin alpha2 | 2 | 10.0 |
Erythrocytes/parasitology/physiology | 3 | 75.0 |
Cytokines/pharmacology | 2 | 0.0 |
Platelet Membrane Glycoproteins/*metabolism | 9 | 8.0 |
*Translocation, Genetic | 2 | 0.0 |
Cell Membrane/immunology | 2 | 0.0 |
Cell Movement/drug effects | 2 | 0.0 |
Antigens, CD34/*analysis | 3 | 1.0 |
Erythropoietin/*pharmacology | 4 | 3.0 |
Chondroitin Sulfates/*metabolism | 5 | 35.0 |
Malaria/*blood | 5 | 35.0 |
Malaria, Falciparum/*blood | 9 | 69.0 |
Clone Cells | 3 | 0.0 |
Receptors, Cell Surface | 2 | 6.0 |
Selection (Genetics) | 2 | 1.0 |
Trypsin/pharmacology | 5 | 3.0 |
Erythrocytes/*metabolism/parasitology | 4 | 80.0 |
Melanoma, Amelanotic | 4 | 80.0 |
Guinea Pigs | 3 | 0.0 |
Membrane Glycoproteins/*biosynthesis/genetics | 2 | 3.0 |
Arachidonic Acid/metabolism/pharmacology | 2 | 33.0 |
Monocytes/*drug effects/metabolism | 3 | 3.0 |
Muscle, Smooth, Vascular/drug effects/*metabolism | 2 | 8.0 |
Cell Survival | 4 | 0.0 |
Antigens, CD36/analysis/genetics | 2 | 100.0 |
Chromosome Disorders | 3 | 0.0 |
HLA Antigens/analysis | 5 | 2.0 |
Epidermis/*cytology | 2 | 6.0 |
HLA-DR Antigens/metabolism | 2 | 1.0 |
Skin/*cytology | 2 | 4.0 |
Collagen/pharmacology | 2 | 1.0 |
Platelet Aggregation/drug effects/*physiology | 3 | 17.0 |
Macrophages/cytology | 2 | 2.0 |
Placenta/parasitology | 2 | 66.0 |
Pregnancy Complications, Parasitic/*parasitology | 2 | 100.0 |
Interferon Type II/pharmacology | 5 | 0.0 |
Monocytes/*immunology | 7 | 1.0 |
Thrombin/*pharmacology | 2 | 1.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/metabolism | 2 | 5.0 |
English Abstract | 14 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Cell Compartmentation | 3 | 0.0 |
Subcellular Fractions/chemistry/metabolism | 2 | 9.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/physiology | 3 | 30.0 |
Platelet Membrane Glycoproteins/*physiology | 8 | 25.0 |
von Willebrand Factor/physiology | 2 | 7.0 |
Cricetulus | 2 | 0.0 |
Cercopithecus aethiops | 5 | 0.0 |
Lipoproteins/*metabolism | 2 | 1.0 |
Melanoma/pathology | 3 | 9.0 |
Receptors, Immunologic/drug effects | 2 | 25.0 |
Integrin alpha4beta1 | 4 | 4.0 |
Receptors, Lymphocyte Homing/physiology | 2 | 9.0 |
Erythrocytes/metabolism/*parasitology | 6 | 66.0 |
Receptors, LDL/genetics | 2 | 2.0 |
Intercellular Adhesion Molecule-1/*biosynthesis | 2 | 4.0 |
Receptors, Immunologic/physiology | 2 | 1.0 |
Platelet Adhesiveness/*physiology | 2 | 9.0 |
Blood Proteins/*genetics/immunology | 2 | 100.0 |
Intercellular Adhesion Molecule-1 | 17 | 7.0 |
Antigens, CD34/analysis | 3 | 0.0 |
Erythropoietin/pharmacology | 2 | 1.0 |
Infant, Premature | 2 | 1.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Erythrocyte Membrane/metabolism | 2 | 3.0 |
Plasmodium falciparum/metabolism/*pathogenicity | 2 | 100.0 |
HLA-DR Antigens/biosynthesis | 2 | 2.0 |
Cell Adhesion/*drug effects | 3 | 5.0 |
Antibodies, Protozoan | 2 | 28.0 |
Malaria, Falciparum/parasitology | 3 | 33.0 |
Chromosome Banding | 2 | 0.0 |
Dimethyl Sulfoxide/pharmacology | 2 | 2.0 |
Fusion Proteins, bcr-abl/genetics | 2 | 4.0 |
*Hematopoiesis | 2 | 1.0 |
In Situ Hybridization | 4 | 0.0 |
Proto-Oncogene Protein c-kit/analysis | 2 | 4.0 |
Translocation, Genetic | 4 | 0.0 |
Intracellular Fluid/metabolism | 2 | 1.0 |
Recombinant Fusion Proteins/pharmacology | 2 | 2.0 |
Thrombospondins | 49 | 48.0 |
Cell Membrane/*metabolism | 2 | 0.0 |
Hela Cells | 2 | 0.0 |
Membrane Glycoproteins/*pharmacology | 2 | 2.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
Endothelium, Vascular/*chemistry | 2 | 10.0 |
von Willebrand Factor/analysis | 5 | 1.0 |
Epithelial Cells | 2 | 0.0 |
Autoantibodies/*blood | 4 | 1.0 |
Antigens, CD36/genetics/*immunology | 3 | 100.0 |
Endothelium, Vascular/*immunology | 8 | 9.0 |
Blood Platelets/*enzymology | 2 | 2.0 |
Macromolecular Substances | 3 | 0.0 |
Models, Molecular | 2 | 0.0 |
Staining and Labeling | 3 | 0.0 |
Membrane Glycoproteins/*physiology | 4 | 1.0 |
Erythrocytes/cytology/*parasitology | 5 | 100.0 |
Centrifugation, Density Gradient | 3 | 0.0 |
Antigens, CD/immunology | 4 | 0.0 |
P-Selectin/blood | 3 | 4.0 |
Phospholipase C/metabolism | 2 | 0.0 |
Platelet Membrane Glycoproteins/metabolism | 3 | 3.0 |
Antigens, CD/*biosynthesis | 3 | 1.0 |
Cell Adhesion Molecules/*biosynthesis | 3 | 3.0 |
Lymphocyte Activation | 8 | 0.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Antibodies, Monoclonal/*immunology | 7 | 0.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Fetal Blood/*immunology | 2 | 2.0 |
Platelet Membrane Glycoproteins/*analysis | 2 | 6.0 |
Adhesiveness | 2 | 11.0 |
Anion Exchange Protein 1, Erythrocyte/*physiology | 2 | 100.0 |
Brain/blood supply | 3 | 8.0 |
Erythrocytes/*cytology/*parasitology | 2 | 100.0 |
Intercellular Adhesion Molecule-1/biosynthesis/physiology | 2 | 100.0 |
Interleukin-4/pharmacology | 3 | 0.0 |
Cell Adhesion Molecules/*analysis | 7 | 5.0 |
Intercellular Adhesion Molecule-1/analysis | 4 | 3.0 |
Membrane Glycoproteins/analysis | 5 | 1.0 |
Splenectomy | 4 | 6.0 |
Octoxynol | 2 | 3.0 |
Phagocytosis/drug effects/*physiology | 2 | 33.0 |
Adipocytes/*metabolism | 2 | 4.0 |
Dexamethasone/pharmacology | 3 | 0.0 |
Macrophage Colony-Stimulating Factor/pharmacology | 5 | 7.0 |
*Down-Regulation | 2 | 0.0 |
Antibodies, Monoclonal/*pharmacology | 2 | 1.0 |
Perfusion | 2 | 0.0 |
Antigens, CD36/*chemistry | 2 | 100.0 |
Neutrophils/*physiology | 3 | 2.0 |
Capillaries/*cytology | 2 | 100.0 |
Cell Adhesion/*physiology | 5 | 4.0 |
Erythrocytes/*parasitology/physiology | 5 | 83.0 |
Antigens, CD1/analysis | 3 | 3.0 |
Antigens, CD3/analysis | 2 | 0.0 |
Antigens, CD4/analysis | 4 | 0.0 |
Antigens, CD45/analysis | 4 | 1.0 |
Antigens, CD8/analysis | 2 | 0.0 |
Lymphocyte Function-Associated Antigen-1/analysis | 2 | 4.0 |
Receptor, Epidermal Growth Factor/analysis | 2 | 1.0 |
S100 Proteins/analysis | 2 | 1.0 |
Skin/*cytology/immunology | 2 | 25.0 |
Platelet Activation/drug effects/*physiology | 2 | 11.0 |
Antigens, CD/immunology/*physiology | 3 | 9.0 |
Antigens, Surface/drug effects | 2 | 33.0 |
Calcitriol/*pharmacology | 2 | 1.0 |
Chemiluminescent Measurements | 2 | 1.0 |
Fluorescence | 2 | 0.0 |
Keratinocytes/*immunology/metabolism | 2 | 50.0 |
Brazil | 2 | 0.0 |
Antigens, Protozoan/*genetics | 2 | 28.0 |
Erythrocyte Membrane/*metabolism | 2 | 2.0 |
Umbilical Veins/cytology | 2 | 0.0 |
Anemia, Sickle Cell/*blood | 3 | 9.0 |
Langerhans Cells/pathology | 2 | 11.0 |
Inversion, Chromosome | 2 | 3.0 |
*Tumor Cells, Cultured | 2 | 2.0 |
Oligodeoxyribonucleotides | 3 | 0.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Antigens, CD31 | 5 | 13.0 |
Cell Separation/methods | 2 | 1.0 |
Interferon-gamma, Recombinant/pharmacology | 2 | 1.0 |
Antigens, Differentiation/analysis | 7 | 2.0 |
*Bone Marrow Cells | 5 | 1.0 |
Fibrin/metabolism | 2 | 3.0 |
Platelet Glycoprotein GPIb-IX Complex/metabolism | 2 | 3.0 |
*Cell Adhesion | 11 | 6.0 |
Endothelium, Vascular/immunology | 2 | 4.0 |
Host-Parasite Relations | 2 | 5.0 |
Immunoglobulins, Fab | 3 | 5.0 |
Cell Membrane/chemistry | 2 | 1.0 |
Cytoplasmic Granules/*chemistry | 2 | 11.0 |
von Willebrand Factor/metabolism | 3 | 1.0 |
Immune Sera | 2 | 0.0 |
Histocompatibility Antigens Class I/biosynthesis | 2 | 4.0 |
Brain/blood supply/parasitology | 3 | 100.0 |
Erythrocytes/*parasitology/ultrastructure | 2 | 100.0 |
Membrane Glycoproteins/chemistry/immunology/*metabolism | 2 | 22.0 |
Antigens, Surface/*metabolism | 2 | 3.0 |
*Signal Transduction | 4 | 0.0 |
Glycoside Hydrolases | 2 | 7.0 |
Cross-Linking Reagents | 2 | 0.0 |
*Cell Differentiation/drug effects | 2 | 6.0 |
Antibody Formation | 2 | 0.0 |
Antigen-Presenting Cells/immunology | 2 | 0.0 |
Gold | 2 | 8.0 |
Macrophages/*immunology | 2 | 0.0 |
E-Selectin/analysis | 2 | 10.0 |
Biopsy, Needle | 2 | 0.0 |
Interleukin-10/metabolism | 2 | 3.0 |
Drug Resistance | 2 | 0.0 |
Lymphocyte Subsets | 2 | 1.0 |
Antibodies, Monoclonal/diagnostic use | 8 | 0.0 |
Methylation | 2 | 0.0 |
Blast Crisis/pathology | 2 | 20.0 |
Megakaryocytes/pathology | 2 | 11.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Endothelium, Vascular/cytology/*physiology | 2 | 3.0 |
Antigens, CD34 | 11 | 1.0 |
Bone Marrow Cells | 5 | 1.0 |
Hematopoietic Stem Cells/*metabolism | 2 | 1.0 |
Temperature | 3 | 0.0 |
Neoplasms/drug therapy | 2 | 3.0 |
*Antigens, Differentiation | 2 | 2.0 |
HLA-DR Antigens/*analysis | 2 | 1.0 |
E-Selectin | 7 | 8.0 |
Monocytes/immunology/*physiology | 3 | 18.0 |
Antigens, CD/biosynthesis/*genetics | 2 | 7.0 |
Cytokines/*pharmacology | 3 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 4 | 1.0 |
Receptors, Cytoadhesin/physiology | 2 | 100.0 |
Receptors, Vitronectin | 3 | 17.0 |
Antigens, CD/genetics/*metabolism | 3 | 3.0 |
Receptors, LDL/genetics/*metabolism | 2 | 7.0 |
Platelet Membrane Glycoproteins/*immunology | 6 | 20.0 |
Hybrid Cells | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
Epidermis/immunology | 2 | 9.0 |
Receptors, Interleukin-2/immunology | 2 | 3.0 |
Skin Diseases/*immunology | 3 | 13.0 |
T-Lymphocytes/*immunology | 3 | 0.0 |
Pilot Projects | 2 | 0.0 |
Serotonin/blood | 2 | 5.0 |
Brain/immunology/parasitology | 2 | 100.0 |
Cell Adhesion Molecules/analysis | 10 | 6.0 |
Receptors, Cytoplasmic and Nuclear/agonists | 2 | 22.0 |
Antigens, Differentiation, B-Lymphocyte/immunology | 2 | 3.0 |
Endothelium, Vascular/parasitology | 2 | 100.0 |
Protozoan Proteins/genetics | 2 | 20.0 |
Antigens, CD/*genetics/metabolism | 3 | 6.0 |
Free Radical Scavengers | 2 | 8.0 |
Receptors, Immunologic/*genetics/metabolism | 2 | 9.0 |
Neurons/metabolism | 2 | 0.0 |
Plasmodium falciparum/immunology/*pathogenicity | 2 | 50.0 |
Integrins/*analysis | 2 | 8.0 |
Antigens, CD/*genetics | 6 | 2.0 |
Restriction Mapping | 2 | 0.0 |
Antigens, Surface/immunology | 3 | 1.0 |
Receptors, Cytoadhesin/*analysis | 2 | 100.0 |
Antigens, CD/*blood | 4 | 2.0 |
Receptors, Cytoadhesin/metabolism | 2 | 50.0 |
Antigens, CD/*physiology | 6 | 1.0 |
Algorithms | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Antigens, Surface/*analysis | 3 | 1.0 |
Macrophages, Alveolar/*immunology | 2 | 4.0 |
Antigens, CD11 | 2 | 2.0 |
Antigens, CD14 | 6 | 2.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 6 | 1.0 |
Skin/immunology/*pathology | 2 | 12.0 |
Blood Cells/*immunology | 2 | 10.0 |
Hyperplasia | 2 | 0.0 |
Keratinocytes/*metabolism | 3 | 3.0 |
Collagen/*pharmacology | 2 | 7.0 |
Lymphocytes/pathology | 2 | 2.0 |
Macrophages/pathology | 2 | 1.0 |
Platelet Membrane Glycoproteins/genetics | 2 | 15.0 |
Platelet Membrane Glycoproteins/*genetics | 4 | 13.0 |
Megakaryocytes/*immunology | 2 | 40.0 |
Antigens, CD/genetics/*physiology | 2 | 5.0 |
Leukemia, Megakaryocytic, Acute/*immunology | 2 | 66.0 |
Antigens, CD/*analysis/genetics/immunology | 2 | 40.0 |
Histocytochemistry | 3 | 0.0 |
*Chromosomes, Human, Pair 7 | 2 | 0.0 |
Biopsy | 4 | 0.0 |
Platelet Membrane Glycoproteins/immunology/*physiology | 2 | 33.0 |
Endothelium, Vascular/cytology/drug effects/*immunology | 2 | 66.0 |
Electrophoresis, Gel, Two-Dimensional | 3 | 0.0 |
Immunoelectrophoresis, Two-Dimensional | 2 | 1.0 |
Platelet Aggregation/*drug effects | 2 | 1.0 |
Vascular Cell Adhesion Molecule-1 | 2 | 2.0 |
DNA/genetics | 4 | 0.0 |
Epitopes | 2 | 0.0 |
Platelet Membrane Glycoproteins/chemistry/immunology/*metabolism | 2 | 100.0 |
Receptors, Cytoadhesin/*metabolism | 3 | 37.0 |
Antibodies | 2 | 0.0 |
Macrophage Activation | 2 | 1.0 |
Platelet Membrane Glycoproteins/genetics/*metabolism | 2 | 25.0 |
Antigens, CD2 | 3 | 0.0 |
Antigens, CD13 | 3 | 5.0 |
Antigens, Differentiation, Myelomonocytic/*analysis | 4 | 3.0 |
Keratinocytes/*immunology | 3 | 17.0 |
Mycosis Fungoides/immunology/pathology | 2 | 66.0 |
Psoriasis/immunology/pathology | 2 | 40.0 |
Purpura/immunology/pathology | 2 | 100.0 |
Skin Neoplasms/immunology/pathology | 2 | 22.0 |
Tuberculosis, Cutaneous/immunology/pathology | 2 | 100.0 |
Urticaria/immunology/pathology | 2 | 100.0 |
Epithelium/chemistry | 4 | 3.0 |
Lectins | 2 | 2.0 |
Mammary Glands, Animal/*chemistry | 2 | 40.0 |
Sex Factors | 2 | 0.0 |
Platelet Membrane Glycoproteins/*isolation & purification | 3 | 75.0 |
Carrier Proteins/physiology | 3 | 2.0 |
DNA/metabolism | 3 | 0.0 |
Plasmodium falciparum/*cytology | 2 | 100.0 |
Malaria, Falciparum/blood/immunology/parasitology | 2 | 100.0 |
Epitopes/immunology | 3 | 0.0 |
Antigens, CD36/*biosynthesis/metabolism | 2 | 100.0 |
Arteriosclerosis/*pathology | 2 | 7.0 |
Protozoan Proteins/chemistry/genetics/*metabolism | 2 | 40.0 |
Lipoproteins, LDL | 2 | 22.0 |
Integrins/analysis | 2 | 4.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2.0 |
Fetal Blood | 2 | 1.0 |
Interleukin-3/*pharmacology | 2 | 1.0 |
*Disease Models, Animal | 2 | 0.0 |
Macaca mulatta/*parasitology | 2 | 100.0 |
Antigens, CD/*blood/genetics | 2 | 28.0 |
Cross Reactions | 2 | 0.0 |
Lung/pathology | 2 | 2.0 |
Myocardium/pathology | 2 | 2.0 |
Antigens, CD1 | 2 | 2.0 |
Dermatitis, Atopic/*immunology | 2 | 4.0 |
Chemotaxis/physiology | 2 | 6.0 |
Gene Expression Profiling/methods | 2 | 2.0 |
Oligonucleotide Array Sequence Analysis/methods | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 2 | 1.0 |
Africa | 2 | 2.0 |
Microscopy, Electron/methods | 2 | 3.0 |
Mammary Glands, Animal/chemistry | 2 | 66.0 |
Antigens, Differentiation/*metabolism | 4 | 3.0 |
Plasmodium falciparum/immunology/*metabolism | 2 | 100.0 |
Antigens, Differentiation/*immunology | 3 | 2.0 |
Luminescent Measurements | 2 | 2.0 |
Carrier Proteins/*physiology | 3 | 1.0 |
Blotting, Western/methods | 2 | 1.0 |
Antigens, CD56 | 2 | 2.0 |
Cell Differentiation/immunology | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Oxygen/metabolism | 2 | 0.0 |
Antibodies, Monoclonal/*diagnostic use | 2 | 0.0 |
Leukemia, Myeloid, Chronic/pathology | 2 | 18.0 |
Erythrocytes/*metabolism | 2 | 0.0 |
Survival Analysis | 2 | 0.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Inflammation | 2 | 0.0 |
Antigens, Differentiation/*physiology | 3 | 3.0 |
Antigens, Surface/*physiology | 3 | 4.0 |
Genome | 2 | 0.0 |
Globins/genetics | 2 | 1.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Glycophorin/metabolism | 2 | 14.0 |
Myocytes, Cardiac/metabolism | 2 | 15.0 |
Acid Anhydride Hydrolases/*physiology | 2 | 100.0 |
Nucleoside-Triphosphatase | 2 | 66.0 |
Organic Anion Transporters/*metabolism | 2 | 40.0 |
Blood Glucose/analysis | 2 | 0.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism | 2 | 2.0 |
Immunoglobulin M/metabolism | 2 | 2.0 |
